Intermittent Explosive Disorder – Cannabis Research

Intermittent Explosive Disorder Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 8 studies associated with Intermittent Explosive Disorder.

Here is a small sampling of Intermittent Explosive Disorder studies by title:

Components of the Intermittent Explosive Disorder Research Dashboard

  • Dosing information available for Intermittent Explosive Disorder
  • Chemotype guidance for treating Intermittent Explosive Disorder with cannabis
  • Synopsis of cannabis research for Intermittent Explosive Disorder
  • Individual study details for Intermittent Explosive Disorder

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Intermittent Explosive Disorder

Description of Intermittent Explosive Disorder

Broadly referred to as impulse control disorders this rubric of conditions include disorder that share a common denominator of poor impulse control. Specific condition such aggressive behavior disorders aka intermittent explosive disorder (IED) is a more clearly defined example. The first clinical iteration of the book that defines mental illness in modern psychiatry the Diagnostic Statistical manual (DSM-1) from 1952 did not define Intermittent Explosive Disorder (IED) as an illness or condition to be treated with medicines but as a ‘reaction’ to frustration that is frequently answered with tantrums or destructive behavior. By the time DSM-V was published in 2013 the “reaction” had long been graduated to the diagnosable condition of intermittent explosive disorder which is now to be treated with a number of prescription drugs each with the potential for significant adverse effects. A change that reflects a willingness to control emotionally motivated behavior via pharmaceuticals.

Disease Classification

Condition: Impulsive Disorder
Disease Family:
Organ System: Mental/Emotional System
ICD-10 Chapter: Mental, Behavioral and Neurodevelopmental disorders
ICD-10 Code: F63

Intermittent Explosive Disorder Symptoms:

Aggressive emotional outbursts disproportional to trigger event, domestic abuse, intimite partner violence, tamper tantrums, non-premeditated impulsive screaming and aggression, tirades, treats to others, assaulting others

Also known as:

Road Rage; Impulse Disorder; Isolated Explosive Disorder; DSM-5: "Disruptive, Impulse-Control, and Conduct Disorders"

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.